AG-1001 / Beijing Aige Stem Cell Technology - LARVOL DELTA

Preclinical Characterization of [ 225 Ac]Ac-AG1001, a Novel SSTR2 Antagonist Radiolabeled with Actinium-225 (EANM 2026) - "Despite the efficacy of Lu-177 DOTATATE, a subset of patients exhibits refractory disease. [225Ac]Ac-AG1001 demonstrates robust preclinical pharmacological profiles with high SSTR2-binding activity, desirable pharmacokinetics, potent anti-tumor efficacy and a favorable safety profile, supporting its progression into clinical development."

Preclinical • Solid Tumor • SSTR • SSTR2

Next-Generation SSTR2-Targeted Antagonist [⁶⁸Ga] Ga-AG1001: A First-in-Human Study on Tracer Uptake, Biodistribution and Dosimetry (EANM 2026) - "[68Ga]Ga-AG1001 exhibits excellent imaging contrast, durable tumor retention, and favorable T/K ratios, with superior uptake in NET lesions. These characteristics support a broad diagnostic window and indicate promising potential for peptide receptor radionuclide therapy using its precursor labeled with therapeutic radionuclides. The tracer is well-tolerated, with a favorable safety profile and acceptable radiation dosimetry."

First-in-human • P1 data • Gastrointestinal Neuroendocrine Tumor • Lung Cancer • Neuroendocrine Tumor • Small Cell Lung Cancer • Solid Tumor • SSTR • SSTR2